Is UniQure (QURE) One of the Promising Stocks to Buy Under $50?

Mizuho expert Uy Ear besides reduced the terms people for UniQure (NASDAQ:QURE) to $33 from $60 earlier connected December 8, portion maintaining an Outperform standing connected the shares. This accommodation followed a large regulatory shift: the FDA informed the institution that existent information from its Phase I/II studies for AMT-130 (a Huntington’s illness cistron therapy) apt lacks the superior grounds required for a BLA.

Consequently, Mizuho lowered its projected probability of occurrence and delayed the expected marketplace motorboat of AMT-130 by 1 year. Despite these hurdles, the steadfast remained optimistic astir the therapy’s semipermanent potential, noting that a follow-up Type A gathering with the FDA is scheduled for Q1 2026 to found a caller way forward.

UniQure (NASDAQ:QURE) develops treatments for patients suffering from uncommon and different devastating diseases successful the US.

While we admit the imaginable of QURE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.